Harold E. Barry Selick

Harold E. “Barry” Selick, Ph.D., joined Hinge Bio as CEO in January 2023. He was most recently the Vice-Chancellor of Business Development, Innovation, and Partnerships at the University of California, San Francisco, a position that he had held since April 2017. Previously, Dr. Selick served as Threshold Pharmaceutical’s Chief Executive Officer from its Series A financing in June 2002 until its sale to Molecular Templates in March 2017. From June 2002 until July 2007, Dr. Selick was also a Venture Partner at Sofinnova Ventures, Inc., a venture capital firm located in San Francisco. From January 1999, he was co-founder and Chief Executive Officer of biotechnology companies Camitro Corporation and its wholly-owned subsidiary, Camitro UK, Ltd, until their sale to ArQule two years later. From 1992 to 1999, he was at Affymax Research Institute, most recently as Vice President of Research where he was responsible for drug discovery and technology development.

During his tenure, Affymax was acquired by Glaxo Wellcome plc as its drug discovery technology development center for which Dr. Selick represented Affymax on the GW Lead Discovery 2000 committee, focused on improving the effectiveness of the company’s global drug discovery process. Before working at Affymax, he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, Inc., he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL’s first product, Zenapax (daclizumab), which was developed and commercialized by Roche for the prevention of kidney transplant rejection. Dr. Selick previously served as a director of Amunix Pharmaceuticals, Lead Director and Chairman of PDL, and as Chairman of Catalyst Biosciences. Aside from Hinge Bio, Dr. Selick currently serves as chairman of the boards of Protagonist Therapeutics as well as Molecular Templates, Inc., both of which are public drug discovery and development companies.

Dr. Selick received his Bachelor of Arts in Biophysics and Doctor of Philosophy in Biology from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.